Carl Batt
· ProfessorCornell University · Food Science
Active 1975–2023
About
Carl A. Batt is a professor in Food Science at Cornell University. His work emphasizes the importance of interdisciplinary approaches and technological innovations to address complex problems in food, agriculture, and environmental processes. His research includes basic and applied studies in protein engineering for developing recombinant anti-cancer therapeutics, the design and engineering of portable sensor devices using micro- and nanofabrication methods, and the development of biomaterials for creating advanced microfluidic systems and nanostructured arrays for bioanalytical applications. Professor Batt's teaching focuses on the role of microorganisms in food, agricultural, and environmental processes, covering their significance in industrial and biotechnological applications as well as food safety and production. His expertise spans multiple graduate fields, including Biomedical Engineering, Comparative Biomedical Sciences, Electrical and Computer Engineering, Food Science and Technology, Materials Science and Engineering, and Microbiology. He holds a doctorate from Rutgers University, a master's degree from Rutgers, and a bachelor's degree from Kansas State University. His research and educational efforts aim to advance scientific understanding and promote societal impact through collaboration with academic, industrial, and governmental institutions worldwide.
Research topics
- Biology
- Genetics
- Internal medicine
- Cancer research
- Medicine
- Immunology
- Virology
- Oncology
Selected publications
Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
2023-04-03
preprintOpen access<div>Abstract<p>The cancer–testis/cancer germline antigen, NY-ESO-1, is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase inhibitors may augment NY-ESO-1 vaccine therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Preclinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1–specific CTL-mediated responses. On the basis of these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 vaccine and doxorubicin liposome chemotherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T-cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in six of ten evaluable patients. On the basis of these encouraging results, evaluation of similar combinatorial chemo-immunotherapy regimens in EOC and other tumor types is warranted. <i>Cancer Immunol Res; 2(1); 37–49. ©2014 AACR</i>.</p></div>
2023-04-03
preprintOpen access<p>PDF file - 59K</p>
2023-04-03
supplementary-materialsOpen access<p>PDF file - 45K, Table S2. Adverse events observed in the clinical trial.</p>
2023-04-03
supplementary-materialsOpen access<p>PDF file - 45K, Table S2. Adverse events observed in the clinical trial.</p>
2023-04-03
preprintOpen access<p>PDF file - 54K, Figure S2. Recognition of naturally processed NY-ESO-1 antigen by NY-ESO-1 specific T cells, pre- and post-therapy.</p>
2023-04-03
preprintOpen access<p>PDF file - 51K, Figure S1. NY-ESO-1-specific CD8+ T cell response to a melanoma cell line.</p>
2023
- Medicine
- Oncology
- Internal medicine
<p>PDF file - 59K</p>
2023-04-03
supplementary-materialsOpen access<p>PDF file - 41K, Table S1. Characteristics of patients enrolled in the clinical trial.</p>
Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
2023-04-03
preprintOpen access<div>Abstract<p>The cancer–testis/cancer germline antigen, NY-ESO-1, is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase inhibitors may augment NY-ESO-1 vaccine therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Preclinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1–specific CTL-mediated responses. On the basis of these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 vaccine and doxorubicin liposome chemotherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T-cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in six of ten evaluable patients. On the basis of these encouraging results, evaluation of similar combinatorial chemo-immunotherapy regimens in EOC and other tumor types is warranted. <i>Cancer Immunol Res; 2(1); 37–49. ©2014 AACR</i>.</p></div>
2023-04-03
preprintOpen access<p>PDF file - 51K, Figure S1. NY-ESO-1-specific CD8+ T cell response to a melanoma cell line.</p>
Recent grants
EAGER: An Interactive Exhibition in Nanotechnology
NSF · $252k · 2009–2011
NIRT: Bioinspired Nanoarchitecture
NSF · $1.2M · 2004–2009
Discovery Corp Senior Fellowship
NSF · $226k · 2007–2012
NSF · $1.9M · 2004–2009
Frequent coauthors
- 58 shared
Gerd Ritter
- 46 shared
Anthony Miliotto
- 46 shared
Stacey N. Akers
- 46 shared
Shashikant Lele
- 45 shared
Adam R. Karpf
University of Nebraska Medical Center
- 45 shared
Wa Zhang
- 44 shared
Amy Beck
- 44 shared
Smitha R. James
Labs
Batt LabPI
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Carl Batt
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup